Danen Technology Corporation (TPE:3686)
Taiwan · Delayed Price · Currency is TWD 16.00
+0.05 (0.31%)
Aug 8, 2025, 2:36 PM CST
Verve Therapeutics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 79.61 | 82.54 | 40.97 | 44.38 | 243.74 | 104.52 | Upgrade | |
Revenue Growth (YoY) | 38.64% | 101.45% | -7.67% | -81.79% | 133.21% | -16.72% | Upgrade |
Cost of Revenue | 80.47 | 83.37 | 41.75 | 45.54 | 110.49 | 126.38 | Upgrade |
Gross Profit | -0.86 | -0.83 | -0.78 | -1.16 | 133.25 | -21.86 | Upgrade |
Selling, General & Admin | 24.4 | 25.08 | 24.21 | 28.7 | 44.98 | 41.28 | Upgrade |
Operating Expenses | 24.28 | 25.01 | 39.8 | 28.7 | 44.98 | 41.28 | Upgrade |
Operating Income | -25.15 | -25.84 | -40.57 | -29.86 | 88.27 | -63.14 | Upgrade |
Interest Expense | -0.04 | -0.02 | -0.05 | -0.08 | -1.37 | -2.04 | Upgrade |
Interest & Investment Income | 10.66 | 11.44 | 10.98 | 4.4 | 0.82 | 1.47 | Upgrade |
Earnings From Equity Investments | 22.4 | 16.87 | - | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | 2.87 | 4.9 | -0.19 | 0.24 | -1.31 | -1.73 | Upgrade |
Other Non Operating Income (Expenses) | - | - | 0.32 | 0.07 | 3.25 | 2.25 | Upgrade |
EBT Excluding Unusual Items | 10.75 | 7.36 | -29.51 | -25.24 | 89.66 | -63.19 | Upgrade |
Gain (Loss) on Sale of Investments | -11.76 | -11.76 | 0.16 | -5.58 | -81.47 | 2.39 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | -28.72 | -90.16 | Upgrade |
Pretax Income | -1.01 | -4.4 | -29.35 | -30.82 | -20.53 | -150.96 | Upgrade |
Income Tax Expense | -0.04 | -0.04 | - | - | - | - | Upgrade |
Earnings From Continuing Operations | -0.98 | -4.36 | -29.35 | -30.82 | -20.53 | -150.96 | Upgrade |
Net Income | -0.98 | -4.36 | -29.35 | -30.82 | -20.53 | -150.96 | Upgrade |
Net Income to Common | -0.98 | -4.36 | -29.35 | -30.82 | -20.53 | -150.96 | Upgrade |
Shares Outstanding (Basic) | 76 | 76 | 76 | 76 | 76 | 76 | Upgrade |
Shares Outstanding (Diluted) | 76 | 76 | 76 | 76 | 76 | 76 | Upgrade |
EPS (Basic) | -0.01 | -0.06 | -0.38 | -0.40 | -0.27 | -1.97 | Upgrade |
EPS (Diluted) | -0.02 | -0.06 | -0.38 | -0.40 | -0.27 | -1.97 | Upgrade |
Free Cash Flow | -15.97 | -8.55 | 39.2 | -115.51 | -43.88 | -39.23 | Upgrade |
Free Cash Flow Per Share | -0.21 | -0.11 | 0.51 | -1.51 | -0.57 | -0.51 | Upgrade |
Gross Margin | -1.08% | -1.00% | -1.90% | -2.62% | 54.67% | -20.92% | Upgrade |
Operating Margin | -31.59% | -31.30% | -99.02% | -67.28% | 36.21% | -60.41% | Upgrade |
Profit Margin | -1.23% | -5.28% | -71.64% | -69.44% | -8.42% | -144.44% | Upgrade |
Free Cash Flow Margin | -20.06% | -10.35% | 95.68% | -260.28% | -18.00% | -37.54% | Upgrade |
EBITDA | -24.95 | -25.65 | -40.29 | -29.57 | 105.9 | -62.68 | Upgrade |
EBITDA Margin | -31.34% | -31.07% | -98.34% | -66.64% | 43.45% | -59.97% | Upgrade |
D&A For EBITDA | 0.2 | 0.19 | 0.28 | 0.28 | 17.63 | 0.47 | Upgrade |
EBIT | -25.15 | -25.84 | -40.57 | -29.86 | 88.27 | -63.14 | Upgrade |
EBIT Margin | -31.59% | -31.30% | -99.02% | -67.28% | 36.21% | -60.41% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.